This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jeremic, B. Articles by Tadic, L. Search for Related Content PubMed PubMed Citation Articles by Jeremic, B. Articles by Tadic, L. Social Bookmarking                            What's this?

Radiation Therapy With or Without Concurrent Low-Dose Daily Chemotherapy in Locally Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck

From the Departments of Oncology and Head and Neck Surgery, University Hospital, Kragujevac, Serbia

Address reprint requests to Branislav Jeremic, MD, PhD, Applied Radiation Biology and Radiotherapy Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Wagramer Strasse 5, P.O. Box 100, A-1400 Vienna, Austria; e-mail: b.jeremic{at}iaea.org

PURPOSE: To retrospectively investigate the difference between conventionally fractionated (CF) and hyperfractionated (Hfx) radiation therapy (RT), with and without either daily cisplatin (CDDP) or carboplatin (CBDCA), in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) enrolled onto two consecutive prospective randomized studies.

PATIENTS AND METHODS: Treatment consisted of CF RT (70 Gy, group 1), CF RT and either daily CDDP (6 mg/m²) or daily CBDCA (25 mg/m²; group 2), Hfx RT (77 Gy, 1.1 Gy bid; group 3), or Hfx RT and daily CDDP (group 4).

RESULTS: Hfx RT plus CDDP achieved better overall survival (OS) and local recurrence-free survival (LRFS) than any other group. There was an insignificant difference favoring Hfx RT over CF RT, either alone or in combination with CDDP or CBDCA, regarding both OS (P = .058 and P = .051, respectively) and LRFS (P = .088 and P = .091, respectively). No difference was seen between CF RT plus chemotherapy (CHT) and Hfx RT alone regarding either OS (P = .32) or LRFS (P = .48). Regional recurrence-free survival was similar in the four treatment groups. CF RT plus CHT and Hfx RT plus CDDP achieved better distant metastasis-free survival than CF RT and Hfx RT. High-grade toxicity was significantly more frequent in Hfx RT plus CDDP than in any other group, except in the Hfx RT group. Hfx RT led to significantly more acute toxicity and xerostomia than CF RT plus CHT. Hfx RT was more toxic than CF RT, either alone or with concurrent CHT.

CONCLUSION: Results of this study show that there may be a therapeutic benefit for CF RT plus CHT over Hfx RT plus CDDP in patients with SCCHN, but this cannot be firmly established without a larger and well-planned controlled trial.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. K. Ang Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes Oncologist, August 1, 2008; 13(8): 899 - 910. [Abstract] [Full Text] [PDF]

				H. Choy, C. Park, and M. Yao Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue Clin. Cancer Res., March 15, 2008; 14(6): 1633 - 1638. [Abstract] [Full Text] [PDF]

				M. R. Posner, D. M. Hershock, C. R. Blajman, E. Mickiewicz, E. Winquist, V. Gorbounova, S. Tjulandin, D. M. Shin, K. Cullen, T. J. Ervin, et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer N. Engl. J. Med., October 25, 2007; 357(17): 1705 - 1715. [Abstract] [Full Text] [PDF]